Effects of salt and fluid restriction on dyspnea in patients with acute decompensated heart failure

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

TCTR

Registry ID

TCTR20200508002

Enrollment

Unknown

Registered

2020-05-08

Start date

2018-11-05

Completion date

Unknown

Last updated

2026-03-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acute decompensated heart failure Salt and fluid restriction Acute heart failure

Interventions

Sodium 1.5 g and fluid 1&#44

000 ml per day restriction,Sodium 3 g and fluid 2&#44

000 ml per day restriction

Active Comparator Dietary Supplement,Active Comparator Dietary Supplement

Group A,Group B

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: - Acute HF patients diagnosed by Framingham criteria - NTproBNP > 450 pg/ml - Hospitalization within 24 hours

Exclusion criteria

Exclusion criteria: 1.Unable to eat or drink by themselve 2.Having other conditions for salt and/or fluid restriction 3.Cardiogenic shock or SBP 3 mg/dL or requiring renal replacement therapy 7.Non-cardiogenic pulmonary edema 8.Digoxin toxicity 9.Sepsis or ongoing systemic infection 10.On mechanical circulatory support 11.Life expectancy least than 1 year 12.Pregnancy 13.Enrollment in another clinical trial involving medical or device-based interventions

Design outcomes

Primary

Measure	Time frame
Difference change of dyspnea 48 hours Visual analog scale	—

Secondary

Measure	Time frame
Biomarkers 48 hours Blood and urine test,Diuretic use 48 hours Total furosemide dose (mg)	—

Countries

Thailand

Contacts

Public ContactNitinan Chimparlee

Faculty of Medicine, Chulalongkorn University

Nitinan.C@chula.ac.th66877856955

Outcome results

None listed

Source: TCTR (via WHO ICTRP) · Data processed: Apr 4, 2026